Biotech Values

[mcbio]

"due-diligence" as a defined process entails, Ask a question in a stepped and methodical analysis to derive an evaluation. One can not evaluate IMO-3100, much less Idera Pharmaceuticals bereft of first acquiring knowledge relevant to the vocabulary employed in your post. For valuation of your post, the reader must understand the the meaning of agonist prior to valuation of your statements:"or these TLR7,8,9 agonists in autoimmune setting" ,and "endpoints there is an inverted dose response curve."

To convey a knowledgable response in this setting requires a vocabulary inclusive of antagonist in addition to agonist and their correct usage. Your comments: "...endpoints there is an inverted dose response curve."; and, "...they would want to run another trial with 3100" are misdirected and invalid for a reader seeking knowledge. Unless there be a deliberate intent to provide DISinformation herein, IMO-3100 is an antagonist and your comments require triaged diligence starting with the pathophysiology linked to the root pharmacology involved. Whatever your long, your post is SHORT on the due-diligence of fundamental knowledge FIRST. Your "experience" is truly ipso facto in this post, but neither a focus nor of value for 'due-diligence' by others in this forum. Your FALSE statement and the absence of experience to appropriately render do engender Risk of Harm should a reader accord TRUST to your BET. My responsibility is limited to sharing of knowledge for the common good.

It's telling that in yet another long, rambling, and largely incoherent post (a bit more understandable this time) you failed to address the most important part of my prior post (#msg-91460868 ). Namely, are you long IDRA? I take it you're upset that I dare question anything about a stock you happen to own. This is yet another call for you to be transparent for the board like I am being.

So, I inadvertently referred to IMO-3100 as an 'agonist' instead of 'antagonist.' My bad man. Why don't you share with the board the meaning of such distinction? What makes IMO-3100 more likely to succeed given that it's an antagonist, as opposed to agonist? Regardless of MoA, the fact remains there is an inverted dose response. And I think that's fair to point out to the board. Does that mean the drug is doomed for failure? No, of course not. But, it is at a very minimum something one should consider.

I will also tell you that readers of this board are much too smart to confuse long posts littered with a few sophisticated words as a sophisticated investor that can add meaningfully to the discussions on this board. I realize that's just your second post so I'll give you some time to realize this.

I couldn't care less if you view my comments as "misdirected" or "invalid." And there is no deliberate intent to provide misinformation. Rather, I'm the one being transparent in telling you I have no position in IDRA either way. Why can't you do the same? Again, it's quite telling. I'm going to keep posting the same way on this board that I have for the past several years. And I don't give a damn if you don't like how I post.